AlphAIAlphAI — Financial news for AI agents
247wallst.com$ZTS

Zoetis Q3 2026: EPS Beats by 16% as Livestock Offsets Pet Softness

Zoetis reported Q3 2026 adjusted EPS of $1.75, beating estimates by 16%, with revenue at $2.39B, up 4% from expectations. Livestock and fish segments grew, offsetting an 8% decline in U.S. companion animal revenue. Net income fell 18% YoY due to one-time charges. The company raised full-year EPS guidance to $6.25-$6.35 and narrowed revenue guidance to $9.22B-$9.32B. Management cited portfolio breadth as a counterweight to companion animal pressure.

Original reporting
247wallst.com
Published Nov 5, 2026, 12:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 1:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Zoetis Q3 2026: EPS Beats by 16% as Livestock Offsets Pet Softness — source image
Source · 247wallst.com
Decision brief

The 30-second read

$ZTSBullishHigh
01

Why it matters

Earnings beat and guidance raise are likely to drive short‑term upside, while segment mix shifts warrant monitoring.

02

Market read

The earnings beat and guidance lift make Zoetis a near‑term buying opportunity for investors in the animal health sector.

03

What to watch

Potential volatility if companion animal segment fails to stabilize; macro pressure on pet owners.

Relevance 8/10Novelty 8/10Timing: post‑market today

Background

Zoetis is the largest animal health company, reporting quarterly results and guidance updates.

Company-level read

Ticker impact

$ZTSBullishHigh confidence
Context

Zoetis reported Q3 2026 adjusted EPS beat by 16% and raised full-year adjusted EPS guidance to $6.25‑$6.35.

Expected impact

upward pressure as investors price in the earnings beat and higher guidance.

Evidence & confidence

The beat and guidance raise improve earnings outlook; one‑time charges are disclosed, limiting downside.

Market effects

Sector

Strong livestock and fish segment performance may boost animal health sector sentiment.

Regional

U.S. animal health investors may see a rally; international livestock growth supports global exposure.

Global

Zoetis is a leading global animal health company; its guidance lift can influence sector ETFs.

Counterpoint

What could challenge this read

The companion animal softness and one‑time impairment charges could signal underlying demand weakness.

Key entities

  • Company
    Zoetis

    Animal health company reporting Q3 2026 results.

  • Executive
    Kristin Peck

    CEO of Zoetis who commented on the quarter.

Read at source← All news

StoryZoetis reports Q3 2026 results, beats EPS and raises full‑year guidance

Also covered by

5 outlets

Related articles

$ZTSMedAI 8/10

Zoetis (ZTS) Q3 2026 Earnings Call Transcript

Zoetis (ZTS) reported Q3 2026 earnings with revenue and adjusted net income declining as expected. The company cited challenges in pet care due to rising costs and changing pet ownership trends, while livestock demand remains strong. Zoetis narrowed its full-year revenue guidance to the high end of its range and highlighted investments in key franchises and innovation.

finance.yahoo.com
$ZTSMedAI 8/10

Zoetis 3Q 2026: Revenue $2.39B, EPS $1.44 — 10-Q Summary

Zoetis reported 3Q 2026 revenue of $2.39B, down 1% YoY, and net income of $1.44B, down 18%. Declines were driven by softer U.S. companion-animal demand, competition, and lower prices, partially offset by livestock growth and favorable exchange rates. Higher restructuring costs also impacted earnings. U.S. companion-animal revenue fell 8%, while U.S. livestock and international revenues rose 5% and 4%, respectively.

tradingview.com
$ZTSHighAI 8/10

Why is Zoetis stock climbing today?

Zoetis (ZTS) stock rose 2.4% premarket after Q3 2026 earnings beat estimates, with adjusted EPS of $1.75 vs. $1.51 and revenue of $2.4B vs. $2.3B. The company raised full-year EPS guidance to $6.25–$6.35. International sales grew 4%, while U.S. companion animal business faced challenges. The stock traded near $91.30 premarket, below its 52-week high of $132.49.

investing.com